Neurocardiogenic syncope. Aetiology and management

• Published in: Drugs (New York, N.Y.) N.Y.), 2001, Vol.61 (10), p.1415-1423
• Main Authors: GATZOULIS, Kostas A, TOUTOUZAS, Pavlos K
• Format: Article
• Language: English
• Subjects: Accidents; Autonomic Nervous System - physiology; Biological and medical sciences; Bradycardia - complications; Bradycardia - etiology; Clinical Trials as Topic; Diagnosis, Differential; Drug Therapy; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Hypotension - complications; Hypotension - etiology; Medical sciences; Nervous system (semeiology, syndromes); Neurology; Pacemaker, Artificial; Patient Care Planning; Syncope - diagnosis; Syncope - etiology; Syncope - therapy; Syncope, Vasovagal - diagnosis; Syncope, Vasovagal - etiology; Syncope, Vasovagal - therapy; Tilt-Table Test
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-200161100-00005

Neurocardiogenic syncope is the most common cause of syncope presenting in the outpatient setting. It is usually encountered among individuals without an underlying heart disease, but not uncommonly participates in the syncope mechanism of patients with an obstructive or an arrhythmic cardiac cause for syncope as well. The vasovagal event is caused by a transient profound hypotensive reaction most commonly associated with inappropriate bradycardia resulting from activation of a complex autonomic reflex. The pathophysiology of neurocardiogenic syncope has been elucidated by tilt table testing, a noninvasive and well-tolerated method for reproducing the event in susceptible individuals. Although the majority of people with vasovagal fainting need no specific treatment, treatment is required for those presenting with problematic features such as frequent events accompanied by trauma or accidents, and occasionally by a severe cardioinhibitory pattern response. A number of different drugs have been proposed to favourably act on different aspects of the neurocardiogenic reflex but only a few randomised, placebo-controlled, drug-specific trials are currently available. Alternatively, cardiac pacing has also been introduced for patients who have symptoms that are drug-refractory or for those with a severe cardioinhibitory hypotensive response. The selection of the appropriate treatment plan should be individualised after consideration of patient history, clinical characteristics and preference, results of the baseline tilting study, and the existing evidence from the few randomised, controlled studies performed so far.